Robert Milligan
Analyst · BMO Capital Markets. Your line is open
Thanks, Amanda. Our financial performance in the third quarter remained strong, as highlighted by improved portfolio performance with same-store NOI growth of 2.5%. Normally, the FFO per share held during the quarter at $0.44, an increase of 2.3% versus 2020. Bringing our year-to-date earnings to $1.32 per share, which is up 3 – over 3% compared to 2020. Our normalized FAD was $78 million and year-to-date normalized FADs up 4% from 2020 to $248 million. Our G&A remained consistent at $10.8 million, less than 10% of NOI. This includes approximately $0.5 million of costs related to our whistleblower investigation, with costs for our new CEO, Chairman compensation being offset by the elimination of unvested shares related to our prior CEO. As a result, we were able to re-conform our previous guidance for the full year tightening the range, but leave the midpoint intact. From a balance sheet perspective, we ended the quarter with $1.2 billion of liquidity and net debt-to-EBITDA of 5.8 times, including the impact of unsettled Ford equity agreements totaling $218 million. In October, we refinanced our $1.3 billion unsecured credit facility, resulting in a reduction in our borrowing cost and an additional four years of term, including extension options. In terms of acquisition activity, we closed on four previously announced MOB acquisitions in the quarter totaling $135 million and an anticipated in place year one yield of 5.7%. These acquisitions increased densification in our key markets and brought our year-to-date investment activity to $188 million. We have an additional $159 million of acquisitions under contract or exclusive letters of intent that we expect to close prior to year-end. Including the $69 million of loan funding commitments to projects in Houston’s Texas Medical Center of $54 million that was funded through third quarter 2021, investment activity is expected to total over $400 million. From a development perspective, in the third quarter, we completed core and shell construction on time in our development project in Dallas with cash rents expected to commence before the end of the year. In addition, we have a development pipeline of five projects in various stages in the pre-leasing process, totaling almost $400 million and over 850,000 square feet of GLA, highlighted by our strategic partnership with Medistar Corporation to codevelop the Horizon Power on the Texas and Innovation Plaza in the Texas Medical Center. Following quarter end, we made a strategic investment in Pivotal analytics, an OptumHealth partner and an innovative company that is applying the tremendous data and insights that can come from the billions of health insurance claims completed on an annual basis to the physical world, with an ultimate goal of improving the decision-making process for healthcare providers around strategic office locations, the impact of referral patterns and also best efforts around service line implementations. While relatively small from a monetary basis at $6 million, this investment in their Series A provides us with a preferred position to grow and utilize the tools being developed by this innovative company. That way, we can leverage – in a way that we can leverage as we execute our strategic plan. Outside the specific numbers in the quarter, we believe HTA is very well-positioned to accelerate our earnings as we head into 2022. This is in part related to several steps that we are intently focused on from a strategic perspective, including investing in our talent and infrastructure. As Peter noted, we will always operate with focus and efficiency. However, we believe that growing the overall capabilities of our team will provide tremendous returns and drive growth within our portfolio and on an external basis. This includes a focus on training and alignment but also an investment in headcount to add additional leasing, investment professionals and market research, also adding additional infrastructure that can help us streamline our operations to add efficiency. Second, we’re focused on markets and data analytics to drive performance. We already have great teams on the ground, but are supplementing that with a greater focus on analytes to drive the depth and intelligence that’s needed to really outperform in ways that improve our capital allocation decision-makingm improving leasing performance and adding value for our customers. Our investment in Pivotal is just one effort that we have undertaken to better position our teams. Third, by aligning capital sources with the reality of the MOB marketplace. Simply put, the public markets do not always value the stable growth of MOBs. To remain competitive, we must diversify our capital sources in ways that enable us to execute on the unique opportunities that we see as the leader in this space. From a practical perspective, this should drive upside growth in the following ways. First, through occupancy upside. Our occupancy was 88% as of September 30. We believe a realistic run rate occupancy for our portfolio is closer to the 92% to 93% range, which is consistent with the broader MOB market and which we have achieved prior to COVID. Achieving this occupancy gain would result in almost 1 million square feet of absorption and could result in $16 million to $20 million in incremental annual NOI. We believe this to be achievable given that some of our highest growth markets currently contain meaningful amounts of occupancy upside, including Houston and Dallas and Charlotte and Phoenix. These four markets, each with strong underlying operating fundamentals account for nearly 900,000 square feet or 1/3 of the 2.7 million square feet of leasable space as of September 30. Second area is by driving development. We believe that the development will come in multiple ways. First, with the traditional health system RFP, where we will compete to win pre-leased projects. However, these are extremely competitive, driving the pricing down. The real opportunity is using our market intelligence from both tenant and local market relationships and our balance sheet flexibility to proactively identify key areas of growth for health care providers and creatively structure medical office opportunities for which providers will compete. Third area is by pursuing joint ventures. Private market interest in medical office has never been higher. As seen across other REIT sectors, partnering with private capital joint venture partners is an attractive path for growth, allowing established public companies to leverage our operating platform and expertise while benefiting from access to currently lower cost private capital. In a space that has seen several regional operators raised $1 billion funds, we believe we are uniquely positioned as a best-in-class operator where many can and should want to partner over the long-term. Fourth area is through asset sales. In addition to the JVs, we’ll be utilize this competitive market to sell assets that no longer fit our strategic plans. These are great assets, just happen to be located on markets or assets for which we believe we maximize value. Assets that we can sell at great pricing and redeploy into other opportunities for the benefit of shareholders. In short, HTA has a number of opportunities on which to execute to drive performance in the short to medium-term. With that, I will now turn it over to Peter to wrap it up.